Parameter | n (%) |
Demographics | |
Number of patients | 15 (100) |
Age (y), mean ± SD | 61.13 ± 11.51 |
Male/female | 9 (60)/6 (40) |
Ethnicity | |
Caucasian | 12 (80) |
Asian | 1 (6.67) |
African-American | 2 (13.33) |
Disease characteristics | |
Tumor entity | |
Intrahepatic cholangiocarcinoma | 2 (13.33) |
Neuroendocrine cancer metastases | 7 (46.67) |
Colorectal cancer metastases | 3 (20) |
Melanoma cancer metastases | 1 (6.67) |
Prostate cancer metastases | 1 (6.67) |
Leiomyosarcoma metastases | 1 (6.67) |
Eastern Cooperative Oncology Group performance status | |
0 | 9 (60) |
1 | 6 (40) |
Main portal vein thrombosis | 1 (6.67) |
Tumor characteristics, median (interquartile range, range) | |
Number of tumors/liver | 11 (5.5–11, 4–129) |
Number of tumors/analyzed lobe | 6 (3.5–6, 1–85) |
TTV (cm3)/analyzed lobe | 102.01 (67.03–300.89, 14.94–1,868.39) |
ETV (cm3)/analyzed lobe | 66.66 (19.54–87.79, 0–839.01) |
Tumor burden/analyzed lobe (%) | 6.1 (5.59–26.73, 1.53–76.86) |
Enhancing tumor burden/ analyzed lobe (%) | 4.38 (2.12–5.45, 0–38.25) |
Previous treatments | |
Systemic therapies | 10 (66.67) |
Resection* | 3 (20) |
TACE* | 1 (6.67) |
Ablation* | 2 (13.33) |
↵* Pretreated tumors are not included in the analysis.